Across malignancies, CAFs exploit autophagy to sustain tumor progression—whether through nucleoside secretion in pancreatic cancer[30] or lipid droplet catabolism during stellate cell activation.[9, 31, 32] ENZ‐treated STEAP4+ myoCAF exhibit elevated levels of autophagy and release PC into tumor cells through TFE3‐dependent autophagy, consistent with prior reports of androgen deprivation‐induced autophagy in prostate cancer cells,[33, 34] although these studies exclusively focused on the autophagy of tumor cells and not on the changes in autophagy of stromal fibroblasts. Here, STEAP4 is linked to prostate cancer.